Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative

Most work on HIV vaccines is being done in the public sector rather than the pharmaceutical industry. Although international cooperation is producing candidate vaccines, greater investment is needed to speed up progress

Saved in:
Bibliographic Details
Published inBMJ Vol. 329; no. 7463; pp. 454 - 456
Main Authors Tucker, Timothy J, Mazithulela, Gatsha
Format Journal Article
LanguageEnglish
Published London British Medical Journal Publishing Group 21.08.2004
British Medical Association
BMJ Publishing Group LTD
BMJ Publishing Group
BMJ Publishing Group Ltd
EditionInternational edition
Subjects
Acquired immune deficiency syndrome
AIDS
AIDS Vaccines
Biological and medical sciences
Clinical trials
Developing countries
Drug Design
Education And Debate
Epidemics
Forecasting
General aspects
Government initiatives
Health Resources - organization & administration
HIV
HIV Infections - prevention & control
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Initiatives
International Cooperation
International development
Interprofessional Relations
Investment strategies
Medical sciences
Private sector
South Africa
Vaccination
Vaccines
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
South Africa
Africa
Infection
Medicine
Prevention
Immunopathology
Immunoprophylaxis
Perspective
Viral disease
Development
AIDS
Vaccine
Immune deficiency
Online AccessGet full text

Cover

More Information
Summary:Most work on HIV vaccines is being done in the public sector rather than the pharmaceutical industry. Although international cooperation is producing candidate vaccines, greater investment is needed to speed up progress
Bibliography:local:bmj;329/7463/454
ArticleID:bmj.329.7463.454
href:bmj-329-454.pdf
PMID:15321907
ark:/67375/NVC-58FRNS1L-T
istex:3ABF492424DBEF390EC81B95C9B2867EEEDEF165
Correspondence to: T J Tucker
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Correspondence to: T J Tucker saavi@mrc.ac.za
Contributors and sources: TT and GM lead the SAAVI team of over 200 people. TT has had extensive experience in running clinical trials, molecular virology research, and public policy development in HIV in South Africa. GM has a background in molecular virology and the management of intellectual property within the biotechnology industry and formal training in business. This paper was developed after multiple presentations about SAAVI in forums describing global public-private partnerships.
Competing interests: None declared.
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.329.7463.454